Nephro Care India Ltd.
Nephro Care India Ltd. (NEPHROCARE-ST.NS) Stock Competitors & Peer Comparison
See (NEPHROCARE-ST.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEPHROCARE-ST.NS | ₹128.00 | -0.43% | 0 | N/A | N/A | N/A |
| APOLLOHOSP.NS | ₹7,720.50 | +0.00% | 1.1T | 61.94 | ₹125.66 | +0.26% |
| APOLLOHOSP.BO | ₹7,718.60 | +0.00% | 1.1T | 61.97 | ₹125.58 | +0.26% |
| MAXHEALTH.BO | ₹1,086.75 | +0.00% | 1.1T | 75.07 | ₹14.51 | +0.14% |
| MAXHEALTH.NS | ₹1,086.40 | +0.00% | 1.1T | 74.94 | ₹14.52 | +0.14% |
| FORTIS.BO | ₹919.95 | +0.00% | 702.7B | 73.35 | ₹12.69 | +0.11% |
| FORTIS.NS | ₹919.55 | +0.00% | 702.7B | 73.35 | ₹12.69 | +0.11% |
| NH.NS | ₹1,821.00 | +0.00% | 378.6B | 48.64 | ₹38.33 | +0.24% |
| NH.BO | ₹1,821.45 | +0.00% | 378.3B | 44.82 | ₹41.56 | +0.24% |
| ASTERDM.BO | ₹637.95 | +0.00% | 332.5B | 100.99 | ₹6.37 | +0.78% |
Stock Comparison
NEPHROCARE-ST.NS vs APOLLOHOSP.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while APOLLOHOSP.NS trades at ₹7,720.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas APOLLOHOSP.NS's P/E ratio is 61.94. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check APOLLOHOSP.NS's competition here
NEPHROCARE-ST.NS vs APOLLOHOSP.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while APOLLOHOSP.BO trades at ₹7,718.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas APOLLOHOSP.BO's P/E ratio is 61.97. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check APOLLOHOSP.BO's competition here
NEPHROCARE-ST.NS vs MAXHEALTH.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MAXHEALTH.BO has a market cap of 1.1T. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MAXHEALTH.BO trades at ₹1,086.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MAXHEALTH.BO's P/E ratio is 75.07. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MAXHEALTH.BO's competition here
NEPHROCARE-ST.NS vs MAXHEALTH.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MAXHEALTH.NS has a market cap of 1.1T. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MAXHEALTH.NS trades at ₹1,086.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MAXHEALTH.NS's P/E ratio is 74.94. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MAXHEALTH.NS's competition here
NEPHROCARE-ST.NS vs FORTIS.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, FORTIS.BO has a market cap of 702.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while FORTIS.BO trades at ₹919.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas FORTIS.BO's P/E ratio is 73.35. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to FORTIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check FORTIS.BO's competition here
NEPHROCARE-ST.NS vs FORTIS.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, FORTIS.NS has a market cap of 702.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while FORTIS.NS trades at ₹919.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas FORTIS.NS's P/E ratio is 73.35. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to FORTIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check FORTIS.NS's competition here
NEPHROCARE-ST.NS vs NH.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, NH.NS has a market cap of 378.6B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while NH.NS trades at ₹1,821.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas NH.NS's P/E ratio is 48.64. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to NH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check NH.NS's competition here
NEPHROCARE-ST.NS vs NH.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, NH.BO has a market cap of 378.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while NH.BO trades at ₹1,821.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas NH.BO's P/E ratio is 44.82. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to NH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check NH.BO's competition here
NEPHROCARE-ST.NS vs ASTERDM.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ASTERDM.BO has a market cap of 332.5B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ASTERDM.BO trades at ₹637.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ASTERDM.BO's P/E ratio is 100.99. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to ASTERDM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ASTERDM.BO's competition here
NEPHROCARE-ST.NS vs ASTERDM.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ASTERDM.NS has a market cap of 332.2B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ASTERDM.NS trades at ₹638.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ASTERDM.NS's P/E ratio is 100.88. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to ASTERDM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ASTERDM.NS's competition here
NEPHROCARE-ST.NS vs MEDANTA.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MEDANTA.NS has a market cap of 310.5B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MEDANTA.NS trades at ₹1,149.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MEDANTA.NS's P/E ratio is 60.41. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to MEDANTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MEDANTA.NS's competition here
NEPHROCARE-ST.NS vs MEDANTA.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MEDANTA.BO has a market cap of 310.4B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MEDANTA.BO trades at ₹1,150.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MEDANTA.BO's P/E ratio is 60.42. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MEDANTA.BO's competition here
NEPHROCARE-ST.NS vs KIMS.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, KIMS.NS has a market cap of 290.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while KIMS.NS trades at ₹735.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas KIMS.NS's P/E ratio is 97.14. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check KIMS.NS's competition here
NEPHROCARE-ST.NS vs KIMS.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, KIMS.BO has a market cap of 290.6B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while KIMS.BO trades at ₹733.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas KIMS.BO's P/E ratio is 96.96. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check KIMS.BO's competition here
NEPHROCARE-ST.NS vs RAINBOW.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, RAINBOW.NS has a market cap of 122.9B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while RAINBOW.NS trades at ₹1,199.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas RAINBOW.NS's P/E ratio is 48.07. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to RAINBOW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check RAINBOW.NS's competition here
NEPHROCARE-ST.NS vs RAINBOW.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, RAINBOW.BO has a market cap of 122.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while RAINBOW.BO trades at ₹1,197.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas RAINBOW.BO's P/E ratio is 47.88. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to RAINBOW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check RAINBOW.BO's competition here
NEPHROCARE-ST.NS vs JLHL.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, JLHL.NS has a market cap of 83.9B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while JLHL.NS trades at ₹1,284.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas JLHL.NS's P/E ratio is 44.35. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to JLHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check JLHL.NS's competition here
NEPHROCARE-ST.NS vs JLHL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, JLHL.BO has a market cap of 83.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while JLHL.BO trades at ₹1,273.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas JLHL.BO's P/E ratio is 44.24. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to JLHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check JLHL.BO's competition here
NEPHROCARE-ST.NS vs HCG.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, HCG.BO has a market cap of 81.8B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while HCG.BO trades at ₹584.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas HCG.BO's P/E ratio is 426.51. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check HCG.BO's competition here
NEPHROCARE-ST.NS vs HCG.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, HCG.NS has a market cap of 81.8B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while HCG.NS trades at ₹584.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas HCG.NS's P/E ratio is 426.43. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to HCG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check HCG.NS's competition here
NEPHROCARE-ST.NS vs YATHARTH.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, YATHARTH.BO has a market cap of 67.2B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while YATHARTH.BO trades at ₹704.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas YATHARTH.BO's P/E ratio is 40.02. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check YATHARTH.BO's competition here
NEPHROCARE-ST.NS vs YATHARTH.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, YATHARTH.NS has a market cap of 67.2B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while YATHARTH.NS trades at ₹704.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas YATHARTH.NS's P/E ratio is 40.08. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check YATHARTH.NS's competition here
NEPHROCARE-ST.NS vs KOVAI.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, KOVAI.BO has a market cap of 56.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while KOVAI.BO trades at ₹5,125.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas KOVAI.BO's P/E ratio is 24.07. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to KOVAI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check KOVAI.BO's competition here
NEPHROCARE-ST.NS vs INDRAMEDCO.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, INDRAMEDCO.BO has a market cap of 37.4B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while INDRAMEDCO.BO trades at ₹401.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas INDRAMEDCO.BO's P/E ratio is 20.46. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to INDRAMEDCO.BO's ROE of +0.31%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check INDRAMEDCO.BO's competition here
NEPHROCARE-ST.NS vs INDRAMEDCO.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, INDRAMEDCO.NS has a market cap of 37.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while INDRAMEDCO.NS trades at ₹401.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas INDRAMEDCO.NS's P/E ratio is 20.40. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to INDRAMEDCO.NS's ROE of +0.31%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to INDRAMEDCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check INDRAMEDCO.NS's competition here
NEPHROCARE-ST.NS vs ARTEMISMED.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ARTEMISMED.BO has a market cap of 36.7B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ARTEMISMED.BO trades at ₹232.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ARTEMISMED.BO's competition here
NEPHROCARE-ST.NS vs ARTEMISMED.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ARTEMISMED.NS has a market cap of 36.6B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ARTEMISMED.NS trades at ₹231.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ARTEMISMED.NS's P/E ratio is 101.40. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ARTEMISMED.NS's competition here
NEPHROCARE-ST.NS vs KOVAI.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to KOVAI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check KOVAI.NS's competition here
NEPHROCARE-ST.NS vs DRAGARWQ.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, DRAGARWQ.BO has a market cap of 22.1B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while DRAGARWQ.BO trades at ₹4,661.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas DRAGARWQ.BO's P/E ratio is 31.80. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check DRAGARWQ.BO's competition here
NEPHROCARE-ST.NS vs SHALBY.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, SHALBY.NS has a market cap of 16.9B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while SHALBY.NS trades at ₹151.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas SHALBY.NS's P/E ratio is 202.04. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to SHALBY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check SHALBY.NS's competition here
NEPHROCARE-ST.NS vs SHALBY.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, SHALBY.BO has a market cap of 16.8B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while SHALBY.BO trades at ₹152.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas SHALBY.BO's P/E ratio is 200.64. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to SHALBY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check SHALBY.BO's competition here
NEPHROCARE-ST.NS vs KMCSHIL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, KMCSHIL.BO has a market cap of 14.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while KMCSHIL.BO trades at ₹84.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas KMCSHIL.BO's P/E ratio is 39.23. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check KMCSHIL.BO's competition here
NEPHROCARE-ST.NS vs MAXINDIA.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MAXINDIA.BO's competition here
NEPHROCARE-ST.NS vs MAXIND.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MAXIND.NS has a market cap of 8.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MAXIND.NS trades at ₹155.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MAXIND.NS's P/E ratio is -5.29. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MAXIND.NS's competition here
NEPHROCARE-ST.NS vs ASARFI.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ASARFI.BO has a market cap of 3.2B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ASARFI.BO trades at ₹163.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ASARFI.BO's P/E ratio is 19.64. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to ASARFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ASARFI.BO's competition here
NEPHROCARE-ST.NS vs LOTUSEYE.NS Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, LOTUSEYE.NS has a market cap of 2.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while LOTUSEYE.NS trades at ₹108.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas LOTUSEYE.NS's P/E ratio is 343.22. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check LOTUSEYE.NS's competition here
NEPHROCARE-ST.NS vs LOTUSEYE.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, LOTUSEYE.BO has a market cap of 2.3B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while LOTUSEYE.BO trades at ₹108.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas LOTUSEYE.BO's P/E ratio is 352.90. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check LOTUSEYE.BO's competition here
NEPHROCARE-ST.NS vs AASHKA.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, AASHKA.BO has a market cap of 1.9B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while AASHKA.BO trades at ₹80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas AASHKA.BO's P/E ratio is 76.92. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check AASHKA.BO's competition here
NEPHROCARE-ST.NS vs LEHIL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check LEHIL.BO's competition here
NEPHROCARE-ST.NS vs JSTL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, JSTL.BO has a market cap of 1.1B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while JSTL.BO trades at ₹65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas JSTL.BO's P/E ratio is -52.24. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check JSTL.BO's competition here
NEPHROCARE-ST.NS vs FORTISMLR.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, FORTISMLR.BO has a market cap of 1B. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while FORTISMLR.BO trades at ₹53.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas FORTISMLR.BO's P/E ratio is 22.42. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to FORTISMLR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check FORTISMLR.BO's competition here
NEPHROCARE-ST.NS vs ASPIRA.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ASPIRA.BO has a market cap of 622.7M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ASPIRA.BO trades at ₹60.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ASPIRA.BO's P/E ratio is 43.84. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to ASPIRA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ASPIRA.BO's competition here
NEPHROCARE-ST.NS vs NGIND.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, NGIND.BO has a market cap of 469.1M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while NGIND.BO trades at ₹140.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas NGIND.BO's P/E ratio is 9.58. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check NGIND.BO's competition here
NEPHROCARE-ST.NS vs MEDINOV.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check MEDINOV.BO's competition here
NEPHROCARE-ST.NS vs CMMHOSP.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, CMMHOSP.BO has a market cap of 298.4M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while CMMHOSP.BO trades at ₹39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas CMMHOSP.BO's P/E ratio is -32.75. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check CMMHOSP.BO's competition here
NEPHROCARE-ST.NS vs TEJNAKSH.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, TEJNAKSH.BO has a market cap of 281.5M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while TEJNAKSH.BO trades at ₹13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas TEJNAKSH.BO's P/E ratio is 20.38. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check TEJNAKSH.BO's competition here
NEPHROCARE-ST.NS vs KKSHL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, KKSHL.BO has a market cap of 245.1M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while KKSHL.BO trades at ₹36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas KKSHL.BO's P/E ratio is -23.84. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check KKSHL.BO's competition here
NEPHROCARE-ST.NS vs SML.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, SML.BO has a market cap of 241.4M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while SML.BO trades at ₹59.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas SML.BO's P/E ratio is -24.19. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to SML.BO's ROE of -1.02%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to SML.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check SML.BO's competition here
NEPHROCARE-ST.NS vs FAMILYCARE.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, FAMILYCARE.BO has a market cap of 179.3M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while FAMILYCARE.BO trades at ₹3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas FAMILYCARE.BO's P/E ratio is -3.42. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check FAMILYCARE.BO's competition here
NEPHROCARE-ST.NS vs GLHRL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, GLHRL.BO has a market cap of 171.7M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while GLHRL.BO trades at ₹17.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas GLHRL.BO's P/E ratio is -7.27. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check GLHRL.BO's competition here
NEPHROCARE-ST.NS vs LOOKS.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, LOOKS.BO has a market cap of 108.3M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while LOOKS.BO trades at ₹10.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas LOOKS.BO's P/E ratio is 51.55. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to LOOKS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check LOOKS.BO's competition here
NEPHROCARE-ST.NS vs ZDHJERK.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, ZDHJERK.BO has a market cap of 100.4M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while ZDHJERK.BO trades at ₹25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas ZDHJERK.BO's P/E ratio is 38.28. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to ZDHJERK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check ZDHJERK.BO's competition here
NEPHROCARE-ST.NS vs GIANLIFE.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, GIANLIFE.BO has a market cap of 88.8M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while GIANLIFE.BO trades at ₹8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas GIANLIFE.BO's P/E ratio is -12.27. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, NEPHROCARE-ST.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check GIANLIFE.BO's competition here
NEPHROCARE-ST.NS vs DLCL.BO Comparison February 2026
NEPHROCARE-ST.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPHROCARE-ST.NS stands at 0. In comparison, DLCL.BO has a market cap of 72.4M. Regarding current trading prices, NEPHROCARE-ST.NS is priced at ₹128.00, while DLCL.BO trades at ₹15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPHROCARE-ST.NS currently has a P/E ratio of N/A, whereas DLCL.BO's P/E ratio is 21.70. In terms of profitability, NEPHROCARE-ST.NS's ROE is N/A, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, NEPHROCARE-ST.NS is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEPHROCARE-ST.NS.Check DLCL.BO's competition here